BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25814083)

  • 1. Managing pregnancy in chronic myeloid leukaemia.
    Palani R; Milojkovic D; Apperley JF
    Ann Hematol; 2015 Apr; 94 Suppl 2():S167-76. PubMed ID: 25814083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of chronic myelogenous leukemia in pregnancy.
    Bhandari A; Rolen K; Shah BK
    Anticancer Res; 2015 Jan; 35(1):1-11. PubMed ID: 25550528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy: part of life in chronic myelogenous leukemia.
    Law AD; Dong Hwan Kim D; Lipton JH
    Leuk Lymphoma; 2017 Feb; 58(2):280-287. PubMed ID: 27389567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Rea D
    Ann Hematol; 2015 Apr; 94 Suppl 2():S149-58. PubMed ID: 25814081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of tyrosine kinase therapy in CML.
    Mahon FX
    Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
    Wang DP; Liang MY; Zhang XH; Wang SM
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):735-9. PubMed ID: 21176552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X; Qin Y; Huang X; Jiang Q
    Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues of imatinib and pregnancy outcome.
    Apperley J
    J Natl Compr Canc Netw; 2009 Nov; 7(10):1050-8. PubMed ID: 19930974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
    Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing timing of secondary tyrosine kinase therapy in chronic myeloid leukemia.
    Radich JP
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S89-94. PubMed ID: 19254886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: follow-up of the case with a review of published reports.
    Alizadeh H; Jaafar H; Kajtár B
    Ann Saudi Med; 2015; 35(6):468-71. PubMed ID: 26657232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations.
    Robertson HF; Buckton MJ; Apperley JF
    Expert Rev Hematol; 2023 May; 16(5):325-332. PubMed ID: 37038615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of pregnant chronic myeloid leukemia patients.
    Abruzzese E; Trawinska MM; de Fabritiis P; Baccarani M
    Expert Rev Hematol; 2016 Aug; 9(8):781-91. PubMed ID: 27352939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
    Klamová H; Marková M; Moravcová J; Sisková M; Cetkovský P; Machová Poláková K
    Leuk Res; 2009 Nov; 33(11):1567-9. PubMed ID: 19580997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors.
    Ross DM; Arthur C; Burbury K; Ko BS; Mills AK; Shortt J; Kostner K
    Intern Med J; 2018 Feb; 48 Suppl 2():5-13. PubMed ID: 29388307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
    Jiang Q; Jiang B; Chen SS; Jiang H; Qin YZ; Lai YY; Shi HX; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):6-9. PubMed ID: 22575184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.
    Gratwohl A; Baldomero H; Passweg J
    Ann Hematol; 2015 Apr; 94 Suppl 2():S177-86. PubMed ID: 25814084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.